시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 저분자 이노베이터 CDMO 시장 보고서(2025년)
Small Molecule Innovator CDMO Global Market Report 2025
상품코드 : 1824461
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,493,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,386,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,279,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

저분자 이노베이터 CDMO 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년에는 CAGR 8.8%로 성장할 전망이며, 849억 1,000만 달러로 성장이 예측됩니다. 예측 기간의 성장은 개인화된 의료 및 표적 요법 증가, 그린케미스트리 및 지속가능성에 대한 주목 증가, 신약 시장 투입까지 시간 단축의 요구, 바이오 의약품 파이프라인 확대, 첨단 요법의 출현에 기인할 것으로 보입니다. 예측 기간 중 주요 동향으로는 가상 및 원격 개발 모델의 대두, 제약 업계에서의 협업 및 제휴 증가, 신흥국 시장에 대한 CDMO 서비스 확대, 제조에 있어서 일회용 기술 활용, CDMO의 전략적 개발 파트너에의 진화 등을 들 수 있습니다.

향후 5년간의 성장률 8.8%라고 하는 예측은 전회 예측으로부터 0.1%라고 하는 미감소를 반영하고 있습니다. 이 감소는 주로 미국과 타국가 간 관세의 영향 때문입니다. 관세 인상은 독일과 이탈리아에서 조달하는 고역가 원약 제조장치 및 봉쇄 시스템의 비용을 끌어올려, 의약품 제조비용을 악화시켜, 신규 치료제의 상업화를 늦추는 것으로, 미국의 의약품 개발에 부담을 줄 가능성이 높습니다. 또한 상호관세와 무역 긴장 제한 및 제한의 격화에 의한 세계 경제와 무역에 대한 악영향으로 그 영향은 보다 광범위하게 미칠 것으로 보입니다.

저분자 이노베이터 CDMO 시장의 성장은 만성 질환의 유병률 증가에 의해 촉진될 것으로 예측됩니다. 만성 질환은 1년 이상 지속되어 지속적인 의료를 필요로 하는 경우가 많아, 증가 경향에 있습니다. 저분자 이노베이터 CDMO 시장은 제약 회사 및 생명 공학 회사에 서비스를 제공하며 만성 질환 치료제 제조에 중요한 역할을 합니다. 2023년 1월 발표된 미생물공학 정보센터(NCBI)의 예측에 따르면 2050년까지 미국에서 적어도 하나의 만성질환을 가진 50세 이상의 인구는 2020년 7,152만 2,000명에서 99.5% 급증하고 1억 4,266만 명에 달할 것으로 예측됩니다. 따라서 만성질환 증가는 저분자 이노베이터 CDMO 시장의 원동력이 되었습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향 및 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁 및 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석 및 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별 및 국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도 및 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹 및 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문 및 전략

제36장 부록

AJY
영문 목차

영문목차

A small molecule innovator Contract Development and Manufacturing Organization (CDMO) refers to a pharmaceutical division that provides contract services for the development and manufacturing of small-molecule drugs. These services are often utilized in clinical trials to gather early relative bioavailability information.

The main product types offered by small molecule innovator CDMOs include small molecule active pharmaceutical ingredient (API) and small molecule drug product. Small molecule API refers to any material or combination of materials intended to be used as an active component in the production of a medication or medical product. The various stages involved in the development and manufacturing process include preclinical, clinical, and commercial stages, and these products are used in therapeutic areas such as cardiovascular disease, oncology, respiratory disorders, neurology, metabolic disorders, infectious disease, and others. The primary customers for small molecule innovator CDMOs are pharmaceutical and biotechnology companies.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The small molecule innovator CDMO market research report is one of a series of new reports from The Business Research Company that provides small molecule innovator CDMO market statistics, including small molecule innovator CDMO industry global market size, regional shares, competitors with a small molecule innovator CDMO market share, detailed small molecule innovator CDMO market segments, market trends and opportunities, and any further data you may need to thrive in the small molecule innovator CDMO industry. This small molecule innovator CDMO market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The small molecule innovator cdmo market size has grown strongly in recent years. It will grow from $56.49 billion in 2024 to $60.7 billion in 2025 at a compound annual growth rate (CAGR) of 7.5%. The growth in the historic period can be attributed to rising demand for outsourcing, increasing complexity of small molecule drugs, increasing focus on time-to-market, cost pressures on pharma companies, and stringent regulatory requirements.

The small molecule innovator cdmo market size is expected to see strong growth in the next few years. It will grow to $84.91 billion in 2029 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to a rise in personalized medicine and targeted therapies, increased focus on green chemistry and sustainability, demand for faster time-to-market for new drugs, expansion of the biopharmaceutical pipeline, and the emergence of advanced therapies. Major trends in the forecast period include the rise of virtual and remote development models, increased collaboration and partnerships in the pharma industry, expansion of CDMO services to emerging markets, utilization of single-use technologies in manufacturing, and evolution of CDMOs into strategic development partners.

The forecast of 8.8% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff escalations are likely to burden U.S. drug development by driving up the cost of high-potency Active Pharmaceutical Ingredient manufacturing equipment and containment systems sourced from Germany and Italy, exacerbating pharmaceutical production costs and delaying novel therapy commercialization. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The growth of the small-molecule innovator CDMO market is expected to be fueled by the increasing prevalence of chronic diseases. Chronic diseases, which last a year or longer and often require continuous medical care, are on the rise. The small-molecule innovator CDMO market plays a crucial role in manufacturing medicines for chronic diseases, providing services to pharmaceutical and biotech companies. Projections from the National Center for Biotechnology Information (NCBI) in January 2023 indicate that by 2050, the number of individuals aged 50 and older with at least one chronic illness in the US is anticipated to surge by 99.5%, reaching 142.66 million, up from 71.522 million in 2020. Thus, the increasing prevalence of chronic diseases serves as a driving force for the small-molecule innovator CDMO market.

The increasing expenditures on research and development (R&D) are anticipated to drive the growth of the small-molecule innovator CDMO market in the future. R&D expenditure refers to the financial resources a company or organization allocates for activities focused on innovation, product development, and technological progress. The small-molecule innovator CDMO market is crucial in supporting this rise by offering specialized and efficient services to pharmaceutical and biotechnology companies, which accelerates drug discovery and development processes. For example, in June 2023, the European Federation of Pharmaceutical Industries and Associations, a Belgium-based trade association and lobbying group, reported that R&D expenditures grew from €42,533 million ($46.79 billion) in 2021 to €44,500 million ($48.95 billion) in 2022, representing an increase of €1,967 million ($2.16 billion). Thus, the rise in R&D expenditures is fueling growth in the small-molecule innovator CDMO market.

A prominent trend in the small-molecule CDMO market is the focus on product innovation. Major companies within this market are adopting innovative products to sustain their positions. In May 2023, Oxford Biomedica, a UK-based company, introduced TetraVecta, a next-generation system for CDMO. This technology addresses previous challenges in medicinal development related to payload size, complexity, or interference, thereby facilitating the advancement of in vivo gene treatments.

Strategic partnerships are emerging as a key approach for major companies in the small-molecule innovator CDMO market to provide contract development and manufacturing organization (CDMO) services. Strategic partnerships involve leveraging each other's strengths and resources for mutual benefits and success. An example of this approach is the partnership between SST Corporation, a US-based pharmaceutical company, and Viwit Pharmaceuticals, a China-based research-based pharmaceutical and chemical company. Through this collaboration, they aim to enhance market growth in North America by expanding offerings, leveraging expertise, increasing capacity, and providing essential regulatory support to strengthen their competitive edge.

In February 2022, Recipharma AB, a Sweden-based pharmaceutical CDMO, acquired Vibalogics for an undisclosed amount. This acquisition allows Recipharm to utilize Vibalogics' expertise in oncolytic viruses, viral vaccines, and viral vector gene treatments, enabling diversification across multiple technologies and modalities. Vibalogics GmbH is a Germany-based pharmaceutical CDMO.

Major companies operating in the small molecule innovator cdmo market include Thermo Fisher Scientific Inc., Boehringer Ingelheim International GmbH, Evonik Industries AG, Lonza Group Ltd. , Labcorp Drug Development, Catalent Inc., Wuxi AppTec Co. Ltd., Asymchem, Siegfried holdings, Recipharm AB, Almac Sciences Ltd., Curia Global Inc., Cambrex Corporation, Piramal Pharma Ltd., Hovione, Corden Pharma GmbH, Alcami Corporation, Lifecore Biomedical Inc., NovaTech LLC, Mikart LLC, Kymanox Corporation, August Bioservices LLC, Lyophilization Technology Inc., LGM Pharma LLC, INCOG BioPharma Services

Asia-Pacific was the largest region in the small molecule innovator CDMO market in 2024. The regions covered in the small molecule innovator cdmo market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the small molecule innovator cdmo market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The small molecule innovator CDMO market includes revenues earned by entities by manufacturing the drug substance and providing innovation and services such as packaging, serialization, and shipment. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Small Molecule Innovator CDMO Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on small molecule innovator cdmo market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for small molecule innovator cdmo ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The small molecule innovator cdmo market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Small Molecule Innovator CDMO Market Characteristics

3. Small Molecule Innovator CDMO Market Trends And Strategies

4. Small Molecule Innovator CDMO Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Small Molecule Innovator CDMO Growth Analysis And Strategic Analysis Framework

6. Small Molecule Innovator CDMO Market Segmentation

7. Small Molecule Innovator CDMO Market Regional And Country Analysis

8. Asia-Pacific Small Molecule Innovator CDMO Market

9. China Small Molecule Innovator CDMO Market

10. India Small Molecule Innovator CDMO Market

11. Japan Small Molecule Innovator CDMO Market

12. Australia Small Molecule Innovator CDMO Market

13. Indonesia Small Molecule Innovator CDMO Market

14. South Korea Small Molecule Innovator CDMO Market

15. Western Europe Small Molecule Innovator CDMO Market

16. UK Small Molecule Innovator CDMO Market

17. Germany Small Molecule Innovator CDMO Market

18. France Small Molecule Innovator CDMO Market

19. Italy Small Molecule Innovator CDMO Market

20. Spain Small Molecule Innovator CDMO Market

21. Eastern Europe Small Molecule Innovator CDMO Market

22. Russia Small Molecule Innovator CDMO Market

23. North America Small Molecule Innovator CDMO Market

24. USA Small Molecule Innovator CDMO Market

25. Canada Small Molecule Innovator CDMO Market

26. South America Small Molecule Innovator CDMO Market

27. Brazil Small Molecule Innovator CDMO Market

28. Middle East Small Molecule Innovator CDMO Market

29. Africa Small Molecule Innovator CDMO Market

30. Small Molecule Innovator CDMO Market Competitive Landscape And Company Profiles

31. Small Molecule Innovator CDMO Market Other Major And Innovative Companies

32. Global Small Molecule Innovator CDMO Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Small Molecule Innovator CDMO Market

34. Recent Developments In The Small Molecule Innovator CDMO Market

35. Small Molecule Innovator CDMO Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기